- CE-certified, Class IIa approval, ensuring safety and compliance with EU medical device regulations.
- Precise, consistent dosing to support clinical confidence.
- Simple, discreet usability, activated by inhalation and suitable for both home and clinical settings.
- Reusable, long-lasting hardware, compatible only with Curaleaf’s EU-GMP liquid extract cartridges.
Jonathan Hodgson, UK Managing Director at Curaleaf International, said:
“For the first time, inhaled liquid cannabis can be administered with controlled precision through a registered handheld device — giving prescribers and patients new confidence in treatment delivery.”
Juan Martinez, International CEO, added:
“This is the next phase of our innovation strategy – building a pharma-grade, precision delivery platform that addresses growing global demand for reliable cannabinoid therapies.”
With the UK launch complete, Curaleaf International continues to collaborate with regulators and healthcare providers worldwide to expand patient access to safe, effective, and clinically integrated cannabis-based treatments. Learn more about the UK launch here.
